

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

Deadline: 26.07.2022

EQA round: E13/22 - Hormones 1

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(306) 17-OH-progesterone	[nmol/L]				4							4	4	100%							4	4	100%
Samples and groups																							
Sample A		6,95	0,93	13	4							4	4	100%	CRV	6,024	0,072	44%	3,37	8,68	4	4	100%
Other					4	0						4									4		
							3x 1/36, 1x 4/183								3x 1/36, 1x 4/183								
Sample B		14,2	3,9	27	4							4	4	100%	CRV	18,58	0,19	44%	10,4	26,8	4	4	100%
Other					4	0						4									4		
							3x 1/36, 1x 4/183								3x 1/36, 1x 4/183								
(303) Aldosterone	[nmol/L]				7							7	7	100%									0
Samples and groups																							
Sample A		1,06	0,16	15	7							7	7	100%									0
Other					7	0						7											
							3x 1/218, 3x 4/164, 1x 4/183																
Sample B		1,41	0,19	14	7							7	7	100%									0
Other					7	0						7											
							3x 1/218, 3x 4/164, 1x 4/183																
(307) DHEA-S	[µmol/L]				15							15	15	100%									0
Samples and groups																							
Sample A		15,8	2,0	12	15							15	15	100%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		17,1	1,0	5,9	7	0	CVPG	16,3	0,18	21%	12,8	19,8											
(60) Roche																							
Other					8	0																	
							1x 4/1, 4x 4/12, 1x 4/29, 1x 4/162, 1x 4/179																
Sample B		8,30	0,81	9,8	15							15	15	100%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		8,74	0,44	5,1	7	0	CVPG	8,41	0,087	21%	6,64	10,2											
(60) Roche																							
Other					8	0																	
							1x 4/1, 4x 4/12, 1x 4/29, 1x 4/162, 1x 4/179																
(302) 17-beta-estradiol	[pmol/L]				28							28	28	100%									28
Samples and groups																							
Sample A		1250	120	9,9	28							28	28	100%	CRV	1269	18	30%	888	1650	28	28	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1110	33	3,0	10	0	CVPG	1110	11	22%	865	1360											10
(1) Abbott																							
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1320	14	1,0	10	0	CVPG	1340	6,0	22%	1040	1640											10
(60) Roche																							
Other					8	0																	8
							4x 4/12, 3x 4/162, 1x 4/179								4x 4/12, 3x 4/162, 1x 4/179								
Sample B		642	43	6,7	28							28	28	100%	CRV	651,3	8,2	30%	455	847	28	28	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		609	28	4,6	10	0	CVPG	613	7,5	22%	478	748											10
(1) Abbott																							
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		665	12	1,8	10	0	CVPG	674	3,5	22%	525	823											10
(60) Roche																							
Other					8	0																	8
							4x 4/12, 3x 4/162, 1x 4/179								4x 4/12, 3x 4/162, 1x 4/179								

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

Test	[unit]	Comparability										Traceability													
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
(200) Ferritin						47							44	40	91%								0		
Samples and groups	[µg/L]																								
Sample A		481	98	20	47							44	43	98%								0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		567	41	7,2	15	0	CVPG	562	7,7	24%	427	697	15												
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		518	54	10	11	0	CVPG	501	4,8	24%	380	622	11												
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		393	34	8,7	5	0	CVPG	374	9,0	24%	284	464	5												
Other					16	0							13												
								3x 4/12, 1x 4/29, 1x 4/149, 1x 4/179, 2x 6/1, 3x 6/58, 4x 6/60, 1x 6/149						44	40	91%							0		
Sample B		78,6	23	30	47																				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		72,1	12	17	15	0	CVPG	71,4	2,3	24%	54,2	88,6	15												
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		95,0	16	16	11	0	CVPG	93,3	2,0	24%	70,9	116	11												
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		51,5	5,9	12	5	0	CVPG	57,1	3,2 ±16,8		40,3	73,9	5												
Other					16	0							13												
								3x 4/12, 1x 4/29, 1x 4/149, 1x 4/179, 2x 6/1, 3x 6/58, 4x 6/60, 1x 6/149																	
(301) Cortisol						30							29	27	93%							30	27	90%	
Samples and groups	[nmol/L]																								
Sample A		570	63	11	30								29	28	97% CRV	586,8	6,8	22%	457	716	30	29	97%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		506	36	7,1	7	0	CVPG	503	6,4	16%	422	584	7									7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		607	35	5,7	13	0	CVPG	592	5,0	16%	497	687	13									13			
Other					10	0							9									10			
								1x 3/200, 4x 4/12, 1x 4/29, 3x 4/162, 1x 4/179									1x 3/200, 4x 4/12, 1x 4/29, 3x 4/162, 1x 4/179						30	27	90%
Sample B		921	95	10	30								29	27	93% CRV	925,9	9,5	22%	722	1130	30	27	90%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		856	47	5,5	7	0	CVPG	859	12	16%	721	997	7									7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		940	79	8,4	13	0	CVPG	929	8,3	16%	780	1080	13									13			
Other					10	0							9									10			
								1x 3/200, 4x 4/12, 1x 4/29, 3x 4/162, 1x 4/179									1x 3/200, 4x 4/12, 1x 4/29, 3x 4/162, 1x 4/179								
(304) Progesterone						27							27	27	100%							27	27	100%	
Samples and groups	[nmol/L]																								
Sample A		45,1	7,3	16	27								27	27	100% CRV	45,07	0,56	26%	33,3	56,8	27	27	100%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		47,7	2,9	6,1	10	0	CVPG	46,6	0,67	20%	37,2	56	10									10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		51,1	1,5	3,0	8	0	CVPG	51,1	0,29	20%	40,8	61,4	8									8			
Other					9	0							9									9			
								4x 4/12, 4x 4/162, 1x 4/179									4x 4/12, 4x 4/162, 1x 4/179								
Sample B		14,4	1,9	13	27								27	27	100% CRV	13,5	0,20	26%	9,99	17,1	27	27	100%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,8	1,2	7,9	10	0	CVPG	14,4	0,28	20%	11,5	17,3	10									10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		16,3	0,52	3,2	8	0	CVPG	16	0,10	20%	12,8	19,2	8									8			
Other					9	0							9									9			
								4x 4/12, 4x 4/162, 1x 4/179									4x 4/12, 4x 4/162, 1x 4/179								

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

Test	[unit]	Comparability											Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(121) Total T3						27							26	23	88%								0	
Samples and groups	[nmol/L]																							
Sample A		6,23	0,82	13	27								26	24	92%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,60	0,47	8,4	10	0	CVPG	5,74	0,25	15%	4,87	6,61	10											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		7,17	0,21	2,9	7	0	CVPG	6,97	0,12	15%	5,92	8,02	7											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		6,57	0,24	3,7	5	0	CVPG	6,68	0,23	15%	5,67	7,69	5											
Other					5	0							4											
								1x 3/200, 1x 4/12, 1x 4/29, 2x 4/179																
Sample B		2,43	0,39	16	27								26	24	92%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		2,11	0,12	5,6	10	0	CVPG	2,15	0,068	15%	1,82	2,48	10											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		2,79	0,09	3,5	7	0	CVPG	2,69	0,050	15%	2,28	3,1	7											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		2,74	0,05	2,2	5	0	CVPG	2,8	0,091	15%	2,38	3,22	5											
Other					5	0							4											
								1x 3/200, 1x 4/12, 1x 4/29, 2x 4/179																
(125) Free T3						47							47	45	96%							0		
Samples and groups	[pmol/L]																							
Sample A		21,3	4,0	19	47								47	45	96%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		19,0	1,4	7,1	18	0	CVPG	19,2	0,25	15%	16,3	22,1	18											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		25,9	0,82	3,2	16	0	CVPG	25,8	0,079	15%	21,9	29,7	16											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		21,2	1,0	4,8	5	0	CVPG	21,2	0,36	15%	18	24,4	5											
Other					8	0							8											
								4x 4/12, 2x 4/29, 2x 4/179																
Sample B		9,46	1,5	16	47								47	46	98%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,33	0,37	4,4	18	0	CVPG	8,29	0,086	15%	7,04	9,54	18											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,2	0,35	3,5	16	0	CVPG	10,1	0,040	15%	8,58	11,7	16											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		11,6	0,22	1,9	5	0	CVPG	11,8	0,14	15%	10	13,6	5											
Other					8	0							8											
								4x 4/12, 2x 4/29, 2x 4/179																
(122) Total T4						25							25	21	84%							25	24	96%
Samples and groups	[nmol/L]																							
Sample A		128	9,5	7,4	25								25	24	96% CRV	132,8	1,4	17%	110	156	25	24	96%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		122	5,7	4,7	10	0	CVPG	122	2,5	13%	106	138	10								10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		129	6,2	4,8	6	0	CVPG	125	3,4	13%	108	142	6								6			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		135	1,8	1,3	5	0	CVPG	137	6,3	13%	119	155	5								5			
Other					4	0							4									4		
								1x 4/12, 1x 4/29, 2x 4/179																
Sample B		248	21	8,6	25								25	22	88% CRV	249,5	2,5	17%	207	292	25	24	96%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		248	26	11	10	0	CVPG	242	12	13%	210	274	10								10			

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(123) TSH					57							56	53	95%							0		
Samples and groups	[mU/L]																						
Sample A		24,0	4,2	18	57							56	53	95%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		20,6	1,1	5,2	24	0	CVPG	20,6	0,14	14%	17,7	23,5	24										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		25,4	0,96	3,8	5	0	CVPG	25	0,26	14%	21,5	28,5	5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		28,1	1,0	3,7	18	0	CVPG	27,8	0,094	14%	23,9	31,7	18										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		25,7	1,5	5,9	5	0	CVPG	25,5	0,40	14%	21,9	29,1	5										
Other					5	0							4										
								1x 3/200, 2x 4/29, 1x 4/149, 1x 4/179															
Sample B		9,96	1,6	16	57							56	54	96%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,50	0,44	5,2	24	0	CVPG	8,53	0,059	14%	7,33	9,73	24										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		9,91	0,14	1,4	5	0	CVPG	10,3	0,10	14%	8,85	11,8	5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		11,7	0,49	4,2	18	0	CVPG	11,5	0,042	14%	9,89	13,2	18										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,3	0,54	5,2	5	0	CVPG	10,3	0,15	14%	8,85	11,8	5										
Other					5	0							4										
								1x 3/200, 2x 4/29, 1x 4/149, 1x 4/179															

st_kn_np

End of report

Printed: 30.07.2022